NCT05470166Completed
Lidocaine Infusion With ERAS Protocol for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity.
Lidocaine Infusion With Enhanced Recovery Program for Pancreatic Cancer Surgery: Effect on Pain and Patient Immunity
Source: ClinicalTrials.gov · Last updated 21 Aug 2024
Brief summary (registry, in English)
The whole world now is directed to implement strategies that enhance the patient's quality of life and prevent tumor relapse. Enhanced recovery after pancreatic surgery (ERAPS) program was found to improve the quality of life as it is an evidence-based protocol designed to standardize and optimize perioperative medical care in order to reduce surgical trauma, perioperative physiological stress, organ dysfunction, reduction of clinical complications, length of hospital stay and the health costs together with increase of patient satisfaction. lidocaine; it is an amide local anaesthetic Recently its use as intravenous perioperative infusion for abdominal cancer surgeries is encouraging, as it significantly reduces postoperative pain, opioid consumption and nausea and vomiting. it also promotes gastrointestinal function recovery, and shortens the postoperative hospital stay. In addition, lidocaine in particular can act directly and indirectly on pancreatic cancer cells and the tumor microenvironment. The investigators suggest that IV lidocaine infusion in combination with ERAPS protocol may achieve better postoperative outcomes after pancreatic surgery for cancer.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 2 Jun 2022
- Start date
- 20 Apr 2022
- Primary completion date
- 17 Jan 2024
- Lead sponsor
- Alexandria University
- Diseases
- Pancreatic cancer
- NCT number
- NCT05470166
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 20 Apr 2022 to the primary completion date, 17 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Opioid tolerant patient or patient receiving nonsteroidal anti-inflammatory drugs within 1 week of surgery or antiarrythmic drugs.
Other illness
- Patients with history of sensitivity to lidocaine,
- Any history of antitumor treatments or chemotherapy before surgery
Other
- Diabetic patients.
- Body weight loss \> 15%.
- Cognitive dysfunction.
- Any contraindication for neuraxial anaesthesia.
Who the study is looking for
- Age 30-70 years
- Both sex.
- American society of anesthesiology (ASA) physical status class II;III.
- Resectable pancreatic tumors.
Age in the registry: 30 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alexandria university Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.